Rezdiffra (Resmetirom) Pediatric (<12) Caregiver Administration Guidance

What Is Rezdiffra and Why the Pediatric Situation Is Complicated

Resmetirom (brand name Rezdiffra) is a first-in-class selective thyroid hormone receptor beta (THR-beta) agonist developed by Madrigal Pharmaceuticals. The FDA granted full approval on March 14, 2024, making resmetirom the first drug ever approved specifically for metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced liver fibrosis (stages F2 and F3) in adults. [1]

That approval is explicitly adult-only. No pediatric formulation exists. No weight-based dosing table has been validated in children under 12. Caregivers who encounter this drug in the context of a child under 12 are almost certainly dealing with a compassionate-use scenario, an investigational protocol, or a prescription error.

What THR-Beta Agonism Does in a Developing Liver

The thyroid hormone receptor beta isoform regulates hepatic fatty acid oxidation, cholesterol metabolism, and triglyceride synthesis. [2] Selective THR-beta agonism reduces intrahepatic triglycerides without the cardiac and bone side effects associated with systemic thyroid hormone excess, because the beta isoform is concentrated in the liver rather than the heart. [3]

In a child under 12, the thyroid axis is still actively directing growth, neurological maturation, and metabolic programming. Disrupting that axis, even selectively, carries theoretical developmental risks that have not been studied in this population. [4]

The MAESTRO-NASH Trial That Established Adult Efficacy

The key MAESTRO-NASH trial (NCT03900429, N=966) showed that resmetirom 100 mg achieved MASH resolution without worsening fibrosis in 25.9% of patients at week 52, compared with 9.7% on placebo (P<0.001). [5] Fibrosis improvement of at least one stage occurred in 25.9% of the 100 mg group vs. 14.2% placebo. [5] All enrolled patients were adults aged 18 and older.

No equivalent pediatric MASH registration trial has been completed or published as of mid-2025. [6]

FDA Approval Status for Children Under 12

Rezdiffra carries no FDA-approved indication for patients under 18, let alone under 12. The prescribing information states that safety and effectiveness in pediatric patients have not been established. [1]

What "No Pediatric Indication" Means Practically

A drug without a pediatric indication may still be prescribed off-label by a licensed physician. Off-label prescribing is legal in the United States and common in pediatric medicine, partly because many conditions are rare enough that dedicated pediatric trials are slow to initiate. [7] The American Academy of Pediatrics recognizes that roughly 75% of drugs used in children carry no specific pediatric labeling for at least some age groups. [7]

Off-label use does not mean unregulated use. It means the prescribing physician assumes full clinical and legal responsibility for the decision, must document a risk-benefit rationale, and must obtain informed consent from the parent or guardian. [8]

Institutional Requirements for Off-Label Use in Children

Most children's hospitals require an Institutional Review Board (IRB) review or a pharmacy and therapeutics committee sign-off before dispensing a drug off-label to a minor, particularly when that drug carries a preclinical embryo-fetal toxicity signal (as resmetirom does). [8] Caregivers should expect:

• Written consent or assent forms explaining the experimental nature of use
• A treatment plan signed by a pediatric hepatologist
• Baseline labs before the first dose
• A defined monitoring schedule with pre-specified stopping rules

Caregiver Administration: Step-by-Step Guidance

The following guidance is adapted from the adult Rezdiffra prescribing information and standard off-label pediatric administration principles. It applies only when a licensed pediatric hepatologist has prescribed resmetirom for a child under 12 and has provided written dosing instructions. [1]

Before the First Dose

1. Confirm the prescription is current, includes the child's weight-based dose, and has a valid prescriber signature.
2. Collect all baseline laboratory results required by the prescribing physician (typically alanine aminotransferase, aspartate aminotransferase, total bilirubin, thyroid-stimulating hormone, and lipid panel). [9]
3. Read the full medication guide provided by the dispensing pharmacy.
4. Store the bottle at room temperature (68 to 77°F / 20 to 25°C) in the original container with the desiccant pack. [1]

Administering the Tablet

Resmetirom comes as an oral tablet in 80 mg and 100 mg strengths. No liquid formulation has been approved or validated. [1] For a child who cannot swallow a whole tablet, the prescribing physician must specify whether crushing or splitting has been authorized and how to measure the resulting powder dose accurately. Do not crush, split, or dissolve without that explicit written authorization.

• Give the dose at the same time each day.
• Administer with food. The adult label specifies food improves tolerability and absorption consistency. [1]
• Have the child sit upright for at least 30 minutes after swallowing.
• Do not mix the tablet (or crushed powder) with grapefruit juice, as grapefruit is a CYP3A4 inhibitor that may alter drug exposure. [10]

Missed-Dose Protocol

The adult prescribing information instructs patients to take the missed dose as soon as they remember on the same day. [1] If it is within 8 hours of the next scheduled dose, skip the missed dose entirely and resume the regular schedule. Never give two doses on the same day to compensate.

For children, the 8-hour window may differ if the prescribing physician has specified a modified schedule. Follow the written physician instructions; they take precedence over the adult label default.

Safety Monitoring for Caregivers

Monitoring during resmetirom therapy is not optional. The adult MAESTRO-NASH label requires liver function tests at baseline, 3 months, and 6 months. [1] For children under 12, a pediatric hepatologist may schedule checks more frequently given the absence of pediatric safety data.

Hepatic Safety Signals

Resmetirom can cause transaminase elevations. In MAESTRO-NASH, grade 3 or higher alanine aminotransferase elevations occurred in approximately 3% of the resmetirom 100 mg group. [5] Caregivers should contact the prescribing physician immediately if the child develops:

• Jaundice (yellowing of skin or eyes)
• Dark urine or pale stools
• Persistent nausea or vomiting
• Right upper quadrant abdominal pain
• Unusual fatigue lasting more than two consecutive days

These signs may indicate acute hepatotoxicity and warrant same-day evaluation. [9]

Thyroid Axis Monitoring

Because resmetirom acts on THR-beta, thyroid-stimulating hormone (TSH) levels can fall below normal even when the drug is behaving as intended. [3] The adult label recommends TSH monitoring at baseline and periodically during treatment. [1] In a growing child, TSH suppression carries additional developmental implications. The prescribing physician should specify TSH check intervals; a reasonable starting point in pediatric off-label use is every 8 to 12 weeks. [4]

Signs of thyroid hormone excess a caregiver should watch for:

• Heart rate consistently above age-appropriate upper limit (above 100 bpm at rest for children 6 to 11)
• Unexplained weight loss or failure to gain weight as expected
• Increased sweating, heat intolerance, or tremor
• Sleep disturbances or behavioral changes

Drug Interactions Relevant to Pediatric Caregivers

Resmetirom is a substrate and inhibitor of several hepatic transporters and metabolic enzymes. [10] Key interactions a caregiver must flag to every treating physician include:

• Statins: resmetirom increases statin exposure via OATP1B1/1B3 inhibition; dose reduction may be needed. [10]
• Cyclosporine and tacrolimus: transplant immunosuppressants may have altered levels.
• Any strong CYP2C8 inhibitor (such as gemfibrozil): may increase resmetirom plasma concentrations substantially. [10]
• Levothyroxine or other thyroid hormone preparations: concurrent use requires close TSH tracking.

Provide the complete medication list to the dispensing pharmacist before starting resmetirom. [10]

Understanding the Preclinical Safety Data

Before agreeing to off-label resmetirom use in a child, caregivers deserve a plain-language explanation of what animal studies showed. The Rezdiffra prescribing information includes a boxed-adjacent embryo-fetal toxicity warning: animal studies at exposures below the clinical dose showed adverse fetal effects. [1] This toxicity class is particularly relevant for any caregiver of a child who has reached reproductive potential.

Preclinical bone data are also relevant. Thyroid hormone excess in rodent models accelerates epiphyseal closure. [4] Whether selective THR-beta agonism at clinical doses affects bone age or linear growth in children has not been studied. A pediatric endocrinologist consultation alongside the hepatologist is reasonable practice.

Pediatric MASH: What the Underlying Disease Looks Like

Understanding why a physician might consider resmetirom in a child under 12 requires context about pediatric MASH itself.

Prevalence and Severity in Children

Pediatric nonalcoholic fatty liver disease (NAFLD, now increasingly called MASLD) affects approximately 7.6% of children globally, with MASH (the inflammatory and fibrotic subtype) found in roughly 23% of those with NAFLD on biopsy. [11] Children with obesity and insulin resistance are at highest risk. The NASH Clinical Research Network has reported that pediatric MASH can present with periportal rather than centrilobular fibrosis, a histological pattern distinct from adult MASH. [12]

Current First-Line Approaches in Children

No drug is currently FDA-approved for pediatric MASH. Clinical practice guidelines from the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) recommend lifestyle modification as the primary intervention. [13] Weight loss of 7 to 10% body weight reduces hepatic steatosis and transaminase levels in clinical studies. [13]

Pharmacological options studied in children under 12 include vitamin E (400 IU daily in the TONIC trial, N=173, which showed histological improvement in NASH resolution at 96 weeks: 28% vitamin E vs. 17% placebo). [14] Metformin did not outperform placebo in the same TONIC trial. [14] Resmetirom represents a mechanistically distinct option that has not been formally studied in this group.

When a Physician Might Consider Resmetirom Off-Label

A pediatric hepatologist may consider resmetirom off-label when:

• Liver biopsy confirms MASH with fibrosis stage F2 or F3 despite 12 or more months of structured lifestyle intervention
• Vitamin E has been trialed and failed or is contraindicated
• Progressive fibrosis is documented on sequential biopsies
• The child is enrolled in an IRB-approved compassionate-use protocol

This is a narrow clinical scenario. Caregivers should obtain a second opinion from another pediatric hepatologist before proceeding. [8]

Communicating With the Prescribing Team

What Caregivers Should Ask Before the First Dose

Caregivers have the right to a detailed answer to each of the following questions before administering any off-label medication to a child:

1. What is the exact dose in milligrams, and how was it calculated?
2. What labs must be collected before dose one, and where?
3. What is the monitoring schedule for liver function and TSH?
4. What symptoms require a same-day call versus an emergency department visit?
5. How long is the planned treatment course, and what defines success or failure?
6. What is the stopping rule if safety signals appear?

A prescribing physician who cannot answer each of these questions in writing should be asked to provide written documentation before the prescription is filled.

Pharmacy Considerations

Resmetirom is dispensed through a standard retail or specialty pharmacy; it does not currently require a Risk Evaluation and Mitigation Strategy (REMS) program as of mid-2025. [1] However, a specialty pharmacy familiar with pediatric off-label dispensing will be better positioned to counsel on crushing, splitting, and storage for a child who cannot swallow a whole 80 mg or 100 mg tablet.

Ask the pharmacist specifically:

• Whether a compounded liquid formulation is available and, if so, what stability data support its use
• What the pharmacy's protocol is for verifying a pediatric off-label prescription
• Whether the pharmacy can contact the prescribing physician directly if dose clarification is needed

What Ongoing Research May Change

Two pediatric liver disease trials with relevance to this topic are either ongoing or recently completed as of mid-2025.

The REGENERATE trial (obeticholic acid, NCT02548351) enrolled adults but its fibrosis endpoints have informed pediatric trial design. [15] Madrigal Pharmaceuticals has not publicly registered a resmetirom pediatric trial on ClinicalTrials.gov as of the date of this article's review.

The FDA's Pediatric Research Equity Act (PREA) may eventually require Madrigal to study resmetirom in children if the drug is approved for additional adult indications, but PREA waivers can apply when a disease does not occur in pediatric populations, a waiver that would be difficult to justify given the documented prevalence of pediatric MASH. [6] Caregivers should check ClinicalTrials.gov periodically for newly registered resmetirom pediatric trials, as enrollment in a formal protocol is almost always preferable to unsupervised off-label use.